Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zoetis (NY:ZTS)

154.11 +1.05 (+0.69%)
Official Closing Price Updated: 7:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Zoetis

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
ZTS Q2 Deep Dive: Market Questions Librela Outlook Amid Double-Digit Growth in Core Franchises
Animal health company Zoetis (NYSE:ZTS) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 4.2% year on year to $2.46 billion. The company expects the full year’s revenue to be around... 
Via StockStory
Got $1,000? 3 Dividend Stocks to Buy and Hold Forever
Dip into a beaten-down market sector for deals on some proven winners. 
Via The Motley Fool
If You'd Invested $1,000 in Zoetis (ZTS) Stock 10 Years Ago, Here's How Much You'd Have Today
The short-term picture has been less rosy than the longer-term one. 
Via The Motley Fool
3 Large-Cap Stocks with Promising Prospects
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth... 
Via StockStory
Earnings Scheduled For August 5, 2025
 
Via Benzinga
How Do Investors Really Feel About Zoetis?
 
Via Benzinga
Is Zoetis Gaining or Losing Market Support?
 
Via Benzinga
2 Stocks to Buy With $5,000 and Hold for a Decade
These two stocks come from completely different industries, but each could boost a long-term investor's returns. 
Via The Motley Fool
Stocks Drop As Trump Tariffs Fuel Inflation, Palantir Hits $400 Billion Value: What's Moving Market Tuesday?
Stocks slipped Tuesday as fresh economic data reignited stagflation fears on Wall Street, overshadowing a blowout quarter from Palantir Technologies Inc. 
Via Benzinga
Topics Economy Government
Zoetis Lifts Outlook As Companion Animal Portfolio Offsets Librela Decline
Zoetis beats Q2 estimates with strong pet product sales and raises full-year guidance despite livestock sales decline and Librela weakness. 
Via Benzinga
Zoetis Surges After Crushing Expectations And Raising Its Outlook
The company raised its adjusted profit guidance by 10 cents at the midpoint and hiked its sales guide by $25 million. 
Via Investor's Business Daily
Discover the top S&P500 movers in Tuesday's pre-market session.
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. 
Via Chartmill
Zoetis (NYSE:ZTS) Posts Better-Than-Expected Sales In Q2, Stock Soars
Animal health company Zoetis (NYSE:ZTS) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 4.2% year on year to $2.46 billion. The company expects the full year’s revenue... 
Via StockStory
1 Top Dividend Growth Stock to Buy and Hold Forever
The demand for this company's products will continue increasing. 
Via The Motley Fool
IDEXX Laboratories Soars: A New Benchmark for Animal Health Diagnostics
IDEXX Laboratories (NASDAQ: IDXX), a global leader in veterinary diagnostics and software, has sent ripples through the financial markets with an astounding 27.5% surge in its stock price. This... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
Zoetis (ZTS) Reports Earnings Tomorrow: What To Expect
Animal health company Zoetis (NYSE:ZTS) will be announcing earnings results this Tuesday morning. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence Government World Trade
Billionaire Terry Smith Sold Fundsmith's Entire Stake in Apple and 11X'd His Position in a Company Whose Addressable Market Can Hit $149 Billion by 2032
The "Warren Buffett of Britain" dumped Buffett's actual No. 1 holding in favor a stock with the legs to run higher. 
Via The Motley Fool
Zoetis (ZTS): Buy, Sell, or Hold Post Q1 Earnings?
Over the last six months, Zoetis’s shares have sunk to $153.39, producing a disappointing 11.4% loss - a stark contrast to the S&P 500’s 5.8% gain. This may have investors wondering how to approach the... 
Via StockStory
Topics Government Stocks World Trade
Winners And Losers Of Q1: Zoetis (NYSE:ZTS) Vs The Rest Of The Branded Pharmaceuticals Stocks
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Zoetis (NYSE:ZTS) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Q1 Earnings Recap: Bristol-Myers Squibb (NYSE:BMY) Tops Branded Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSE:BMY) and the best... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Assessing Zoetis: Insights From 4 Financial Analysts
 
Via Benzinga
1 Cash-Producing Stock with Competitive Advantages and 2 to Avoid
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
Phibro's Feed Play Pays Off: JPMorgan Upgrades On Zoetis Deal Boost
Phibro Animal Health gains JPMorgan upgrade as analyst forecasts continued growth across key livestock products and long-term fundamentals. 
Via Benzinga
3 Magnificent S&P 500 Dividend Stocks Down 19% to 26%: Is It Time to Buy the Dip?
Via The Motley Fool
Topics Initial Public Offering Stocks
2 Dividend Growth Stocks to Buy and Hold Forever
Via The Motley Fool
3 Safe-and-Steady Stocks on Our Watchlist
By avoiding big swings, low-volatility stocks let investors focus on long-term fundamentals. These stocks may not be up 100% in a single year, but they offer a measured approach to building wealth over... 
Via StockStory
2 of Wall Street’s Favorite Stocks to Research Further and 1 to Question
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
Elanco Animal Health Gets Its Bite Back, Pipeline Efforts Earn Praise
Elanco upgraded to Outperform by William Blair as pipeline gains traction and EMA backs Zenrelia ahead of expected Q3 approval. 
Via Benzinga
2 S&P 500 Stocks on Our Watchlist and 1 to Think Twice About
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural... 
Via StockStory
Topics Stocks
Forecasting The Future: 4 Analyst Projections For Zoetis
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.